September 11, 2020
Chugai Pharmaceutical said on September 10 that a post-hoc analysis of global PIII studies found that Enspryng (satralizumab), a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody, reduced the risk and severity of relapse by 79% compared to placebo in patients...read more